tiprankstipranks
Blurbs

Analysts Are Neutral on These Healthcare Stocks: Ionis Pharmaceuticals (IONS), Radius Health (RDUS)

Analysts fell to the sidelines weighing in on Ionis Pharmaceuticals (Research Report) with neutral ratings, indicating that the experts are neither bullish nor bearish on the stocks.

Ionis Pharmaceuticals (IONS)

SVB Securities analyst Mani Foroohar reiterated a Hold rating on Ionis Pharmaceuticals on August 9. The company’s shares closed last Wednesday at $46.11, close to its 52-week high of $46.15.

According to -14.9% and a 40.3% success rate. Foroohar covers the Healthcare sector, focusing on stocks such as 4D Molecular Therapeutics, Arrowhead Pharmaceuticals, and Recursion Pharmaceuticals.

Currently, the analyst consensus on Ionis Pharmaceuticals is a Hold with an average price target of $49.10, which is a 9.8% upside from current levels. In a report released yesterday, Barclays also maintained a Hold rating on the stock with a $42.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Radius Health (RDUS)

In a report issued on August 9, David Risinger from SVB Securities maintained a Hold rating on Radius Health, with a price target of $10.00. The company’s shares closed last Wednesday at $10.08.

According to 3.2% and a 47.6% success rate. Risinger covers the Healthcare sector, focusing on stocks such as Vertex Pharmaceuticals, Prometheus Biosciences, and Horizon Therapeutics.

Radius Health has an analyst consensus of Hold, with a price target consensus of $9.40.

Kymera Therapeutics (KYMR)

In a report issued on August 9, Mike Kratky from SVB Securities reiterated a Hold rating on Kymera Therapeutics, with a price target of $26.00. The company’s shares closed last Wednesday at $34.05.

According to 3 stocks are most likely to make moves following their insider activities.

Read More on IONS:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More